API | losmapimod

losmapimod Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Losmapimod (GW856553X) is an investigational drug being developed by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD); a phase III clinical trial is pending approval. Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation. ^Wikipedia

Chemistry

SMILES: Cc1c(F)cc(cc1c2ccc(cn2)C(=O)NCC(C)(C)C)C(=O)NC3CC3
InChIKey: KKYABQBFGDZVNQ-UHFFFAOYSA-N
Mol. Mass: 383.47
ALogP: 3.86 Partition coefficient
ChEMBL Molecule:
losmapimod

More Chemistry

Pharmacology

Mechanisms of Action:
- Mitogen-activated protein kinase 14 (Homo sapiens) ^UniProt
- Mitogen-activated protein kinase 11 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | gs856553 | gskahab | gsk-ahab | gw856553 | gw856553x | losmapimod

Organizations (6)

Research & Development (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (12)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (12)

Acute Coronary Syndrome (Phase 3)

Arthritis, Rheumatoid (Phase 2)

Atherosclerosis (Phase 2)

Cardiovascular Diseases (Phase 1)

COVID-19 (Phase 3)

Depressive Disorder, Major (Phase 2)

Dyslipidemias (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Healthy Volunteers (Phase 2)

Muscular Dystrophies (Phase 3)

Neuralgia (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 28
# of Trial Organizations: 6

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue